eBook: Beyond Monoclonal Antibodies

Exploring the Next Generation of Antibody Therapeutics

Evolution of monoclonal antibodies (mAbs) has resulted in the next generation of antibody therapeutics, engineered to enhance characteristics such as target cell killing potency. These include antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and nanobodies.

It is important to have robust, high-throughput methods to screen antibody libraries if we are to keep up with the broad and ever-changing disease landscape. To discover effective treatments for rare diseases or against poorly expressed targets, we may need to screen antibody binding, and functional capacity across huge hybridoma or phage display libraries. In addition, if we are to respond rapidly in scenarios such as the COVID-19 pandemic, we need techniques that will identify antibodies with desirable characteristics early in the drug discovery process, in order to quickly send high-quality candidates into the clinical evaluation pipeline.

The iQue^® Advanced Flow Cytometry Platform provides an integrated solution, with rapid sampling from 96- and 384-well plates, combined with assay miniaturization. Fast and easy data analysis using iQue Forecyt^® software, decreases instrument and data analysis times.